Automated Lugano Metabolic Response Assessment in 18F-Fluorodeoxyglucose-Avid Non-Hodgkin Lymphoma With Deep Learning on 18F-Fluorodeoxyglucose-Positron Emission Tomography

被引:7
|
作者
Jemaa, Skander [1 ]
Ounadjela, Souhila [1 ]
Wang, Xiaoyong [1 ]
El-Galaly, Tarec C. [2 ,3 ,4 ,5 ]
Kostakoglu, Lale [6 ]
Knapp, Andrea [7 ]
Ku, Grace [1 ]
Musick, Lisa [1 ]
Sahin, Denis [7 ]
Wei, Michael C. [1 ]
Yin, Shen [1 ]
Bengtsson, Thomas [8 ]
De Crespigny, Alex [1 ]
Carano, Richard A. D. [1 ]
机构
[1] Genentech Inc, South San Francisco, CA 94080 USA
[2] Aalborg Univ Hosp, Dept Hematol, Aalborg, Denmark
[3] Odense Univ Hosp, Dept Hematol, Hematol Res Unit, Odense, Denmark
[4] Univ Southern Denmark, Dept Clin Res, Odense, Denmark
[5] AI Sweden, Lund, Sweden
[6] Univ Virginia, Dept Radiol & Med Imaging, Charlottesville, VA USA
[7] F Hoffmann La Roche, Basel, Switzerland
[8] Univ Calif Berkeley, Dept Stat, Berkeley, CA USA
关键词
ARTIFICIAL-INTELLIGENCE; LUNG-CANCER; PET/CT; DLBCL; CONSENSUS; CRITERIA;
D O I
10.1200/JCO.23.01978
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE Artificial intelligence can reduce the time used by physicians on radiological assessments. For F-18-fluorodeoxyglucose-avid lymphomas, obtaining complete metabolic response (CMR) by end of treatment is prognostic. METHODS Here, we present a deep learning-based algorithm for fully automated treatment response assessments according to the Lugano 2014 classification. The proposed four-stage method, trained on a multicountry clinical trial (ClinicalTrials.gov identifier: NCT01287741) and tested in three independent multicenter and multicountry test sets on different non-Hodgkin lymphoma subtypes and different lines of treatment (ClinicalTrials.gov identifiers NCT02257567, NCT02500407; 20% holdout in ClinicalTrials.gov identifier NCT01287741), outputs the detected lesions at baseline and follow-up to enable focused radiologist review. RESULTS The method's response assessment achieved high agreement with the adjudicated radiologic responses (eg, agreement for overall response assessment of 93%, 87%, and 85% in ClinicalTrials.gov identifiers NCT01287741, NCT02500407, and NCT02257567, respectively) similar to inter-radiologist agreement and was strongly prognostic of outcomes with a trend toward higher accuracy for death risk than adjudicated radiologic responses (hazard ratio for end of treatment by-model CMR of 0.123, 0.054, and 0.205 in ClinicalTrials.gov identifiers NCT01287741, NCT02500407, and NCT02257567, compared with, respectively, 0.226, 0.292, and 0.272 for CMR by the adjudicated responses). Furthermore, a radiologist review of the algorithm's assessments was conducted. The radiologist median review time was 1.38 minutes/assessment, and no statistically significant differences were observed in the level of agreement of the radiologist with the model's response compared with the level of agreement of the radiologist with the adjudicated responses. CONCLUSION These results suggest that the proposed method can be incorporated into radiologic response assessment workflows in cancer imaging for significant time savings and with performance similar to trained medical experts.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Contrast-enhanced MRI for the assessment of myocardial viability:: comparison with 18F-fluorodeoxyglucose-positron emission tomography
    Kühl, HP
    Beek, AM
    van der Weerdt, AP
    Visser, CA
    Visser, FC
    van Rossum, AC
    EUROPEAN HEART JOURNAL, 2002, 23 : 304 - 304
  • [42] Neurolymphomatosis - Rare presentation in non-Hodgkin's lymphoma: The role of18F-fluorodeoxyglucose positron-emission tomography and computerized tomography imaging
    Fatima, Nosheen
    Zaman, Maseeh Uz
    Zaman, Areeba
    Zaman, Sidra Uz
    WORLD JOURNAL OF NUCLEAR MEDICINE, 2020, 19 (02) : 159 - 161
  • [43] Herniated urinary bladder detected on 18F-fluorodeoxyglucose positron-emission tomography/computed tomography scan imitating as 18F-fluorodeoxyglucose avid lesion
    Gupta, Nitin
    Verma, Ritu
    Belho, Ethel
    INDIAN JOURNAL OF NUCLEAR MEDICINE, 2020, 35 (02): : 172 - 173
  • [44] Is [18F]fluorodeoxyglucose positron emission tomography the ultimate tool for response and prognosis assessment?
    Brepoels, Lieselot
    Stroobants, Sigrid
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2007, 21 (05) : 855 - +
  • [45] Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Extranodal Staging of Non-Hodgkin Lymphoma and Hodgkin Disease
    Omur, O.
    Yusufoglu, B.
    Oral, A.
    Ceylan, Y.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S372 - S372
  • [46] 18F-fluorodeoxyglucose-positron emission tomography in the staging of malignant lymphoma compared with CT and 67Ga scan
    Hong, SP
    Hahn, JS
    Lee, JD
    Bae, SW
    Youn, MJ
    YONSEI MEDICAL JOURNAL, 2003, 44 (05) : 779 - 786
  • [47] Usefulness of 18F-fluorodeoxyglucose positron emission tomography in follicular lymphoma management
    Le Dortz, L.
    de Guibert, S.
    Devillers, A.
    Rolland, Y.
    Bayat, S.
    Prigent, F.
    Bahri, H.
    Hervouet, T.
    Lamy, T.
    Garin, E.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2009, 33 (06): : 363 - 374
  • [48] Dealing with bone marrow biopsies in the staging of classical Hodgkin lymphoma: an old issue revisited in the 18F-fluorodeoxyglucose-positron emission tomography era
    Goncalves, Marianne de Castro
    de Paula, Henrique Moura
    Gouveia Linardi, Camila da Cruz
    Cerci, Juliano J.
    Aldred, Vera Lucia
    Coelho Siqueira, Sheila Aparecida
    Buccheri, Valeria
    Nogueira Zerbini, Maria Claudia
    LEUKEMIA & LYMPHOMA, 2015, 56 (10) : 2883 - 2888
  • [49] F-18 fluorodeoxyglucose positron emission tomography in mesenterial Castleman's lymphoma
    Kunishima, S
    Taniguchi, H
    Koh, T
    Yamaguchi, A
    Yamagishi, H
    CLINICAL NUCLEAR MEDICINE, 2001, 26 (09) : 789 - 790
  • [50] The Role of Metabolic Monitoring after Radiation Therapy by 18F-fluorodeoxyglucose-Positron Emission Tomography in Patients with Spinal Metastases
    Choi, J.
    Kim, J. W.
    Lee, I. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E67 - E68